Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
TVRD
TVRD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
TVRD News
Tvardi Therapeutics Q1 Earnings Report Analysis
2d ago
seekingalpha
Tvardi Reports Clinical Progress on TTI-109 Inhibitor
2d ago
Newsfilter
Tvardi Therapeutics Reports 2025 Financial Results and Pipeline Progress
Apr 01 2026
NASDAQ.COM
Tvardi Therapeutics Q4 Earnings Miss Expectations
Mar 31 2026
seekingalpha
Tvardi to Present TTI-101 Clinical Data at 44th J.P. Morgan Healthcare Conference
Jan 08 2026
Globenewswire
Tvardi Therapeutics Shares Plunge 80% Following Disappointing Phase 2 Trial Data
Dec 24 2025
Globenewswire
Faruqi & Faruqi Investigates Potential Claims Against Tvardi Therapeutics (NASDAQ:TVRD)
Dec 23 2025
PRnewswire
Tvardi Therapeutics Shares Plunge 80% Following Phase 2 Trial Disappointment
Dec 21 2025
Businesswire
Tvardi Therapeutics Shares Plunge 80% After Phase 2 Trial Disappointment
Dec 20 2025
Globenewswire
Faruqi & Faruqi Investigates Claims for Investors in Tvardi Therapeutics Following Significant Losses
Dec 17 2025
PRnewswire
Faruqi & Faruqi Investigates Potential Claims Against Tvardi Therapeutics (NASDAQ:TVRD)
Dec 11 2025
PRnewswire
Faruqi & Faruqi Investigates Investor Losses in Tvardi Therapeutics
Dec 04 2025
PRnewswire
Faruqi & Faruqi Investigates Investor Losses in Tvardi Therapeutics
Nov 30 2025
PRnewswire
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Looks into Claims for Tvardi Therapeutics Investors
Nov 29 2025
Globenewswire
Investor Alert: Faruqi & Faruqi, LLP Probes Allegations for Tvardi Therapeutics Investors
Nov 20 2025
Globenewswire
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Tvardi
Nov 14 2025
PRnewswire
Show More News
